• Something wrong with this record ?

Haemanthamine alters sodium butyrate-induced histone acetylation, p21WAF1/Cip1 expression, Chk1 and Chk2 activation and leads to increased growth inhibition and death in A2780 ovarian cancer cells

M. Seifrtová, R. Havelek, L. Cahlíková, D. Hulcová, N. Mazánková, M. Řezáčová,

. 2017 ; 35 (-) : 1-10. [pub] 20170819

Language English Country Germany

Document type Journal Article

BACKGROUND: Haemanthamine (HA) and sodium butyrate (NaB) are promising candidates for chemotherapy as a treatment for cancer. PURPOSE: We aimed to determine the anticancer potential of HA and NaB, alone and in combination, in A2780 ovarian cancer cells and concurrently investigated anticancer potential in contrast to non-cancer human MRC-5 fibroblasts. METHODS: Antiproliferative effects were determined by WST-1 assay and by Trypan blue exclusion staining. Cell cycle distributions were studied by flow cytometry and protein levels were determined by Western blotting. RESULTS: The combination of HA and NaB caused a significant decrease in the proliferation of A2780 cells compared to the stand-alone treatment of cells by HA or NaB. This effect was less pronounced in non-cancer MRC-5 fibroblasts. In the later intervals, the number of A2780 living cells was strongly decreased by treatment using a combination of NaB and HA. This simultaneous application had no considerable effect in MRC-5 fibroblasts. The combination of NaB and HA led to the suppression of cells in the G1 phase and caused an accumulation of cells in the S and G2 phase in comparison to those treated with NaB and HA alone. Treatment of cells with NaB alone led to the activation of proteins regulating the cell cycle. Notably, p21WAF1/Cip1 was upregulated in both A2780 and MRC-5 cells, while checkpoint kinases 1 and 2 were activated via phosphorylation only in A2780 cells. Unexpectedly, NaB in combination with HA suppressed the phosphorylation of Chk2 on threonine 68 and Chk1 on serine 345 in A2780 cells and downregulated p21WAF1/Cip1 in both tested cell lines. The sensitization of cells to HA and NaB treatment seems to be accompanied by increased histone acetylation. NaB-induced acetylation of histone H3 and H4 and histone acetylation increased markedly when a combination of NaB and HA was applied. Whereas the most prominent hyperacetylation after HA and NaB treatment was observed in A2780 cells, the acetylation of histones occurred in both cell lines. CONCLUSION: In summary, we have demonstrated the enhanced activity of HA and NaB against A2780 cancer cells, while eliciting no such effect in non-cancer MRC-5 cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016293
003      
CZ-PrNML
005      
20180521091657.0
007      
ta
008      
180515s2017 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.phymed.2017.08.019 $2 doi
035    __
$a (PubMed)28991639
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Seifrtová, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Kralove 500 38, Czech Republic. Electronic address: seifrtovam@lfhk.cuni.cz.
245    10
$a Haemanthamine alters sodium butyrate-induced histone acetylation, p21WAF1/Cip1 expression, Chk1 and Chk2 activation and leads to increased growth inhibition and death in A2780 ovarian cancer cells / $c M. Seifrtová, R. Havelek, L. Cahlíková, D. Hulcová, N. Mazánková, M. Řezáčová,
520    9_
$a BACKGROUND: Haemanthamine (HA) and sodium butyrate (NaB) are promising candidates for chemotherapy as a treatment for cancer. PURPOSE: We aimed to determine the anticancer potential of HA and NaB, alone and in combination, in A2780 ovarian cancer cells and concurrently investigated anticancer potential in contrast to non-cancer human MRC-5 fibroblasts. METHODS: Antiproliferative effects were determined by WST-1 assay and by Trypan blue exclusion staining. Cell cycle distributions were studied by flow cytometry and protein levels were determined by Western blotting. RESULTS: The combination of HA and NaB caused a significant decrease in the proliferation of A2780 cells compared to the stand-alone treatment of cells by HA or NaB. This effect was less pronounced in non-cancer MRC-5 fibroblasts. In the later intervals, the number of A2780 living cells was strongly decreased by treatment using a combination of NaB and HA. This simultaneous application had no considerable effect in MRC-5 fibroblasts. The combination of NaB and HA led to the suppression of cells in the G1 phase and caused an accumulation of cells in the S and G2 phase in comparison to those treated with NaB and HA alone. Treatment of cells with NaB alone led to the activation of proteins regulating the cell cycle. Notably, p21WAF1/Cip1 was upregulated in both A2780 and MRC-5 cells, while checkpoint kinases 1 and 2 were activated via phosphorylation only in A2780 cells. Unexpectedly, NaB in combination with HA suppressed the phosphorylation of Chk2 on threonine 68 and Chk1 on serine 345 in A2780 cells and downregulated p21WAF1/Cip1 in both tested cell lines. The sensitization of cells to HA and NaB treatment seems to be accompanied by increased histone acetylation. NaB-induced acetylation of histone H3 and H4 and histone acetylation increased markedly when a combination of NaB and HA was applied. Whereas the most prominent hyperacetylation after HA and NaB treatment was observed in A2780 cells, the acetylation of histones occurred in both cell lines. CONCLUSION: In summary, we have demonstrated the enhanced activity of HA and NaB against A2780 cancer cells, while eliciting no such effect in non-cancer MRC-5 cells.
650    _2
$a acetylace $7 D000107
650    _2
$a alkaloidy amarylkovitých $x farmakologie $7 D047151
650    _2
$a kyselina máselná $x farmakologie $7 D020148
650    _2
$a buněčný cyklus $x účinky léků $7 D002453
650    _2
$a buněčné dělení $x účinky léků $7 D002455
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a checkpoint kinasa 1 $x metabolismus $7 D000071877
650    _2
$a checkpoint kinasa 2 $x metabolismus $7 D064447
650    _2
$a inhibitor p21 cyklin-dependentní kinasy $x metabolismus $7 D050759
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a histony $x metabolismus $7 D006657
650    _2
$a lidé $7 D006801
650    _2
$a nádory vaječníků $x patologie $7 D010051
650    _2
$a fenantridiny $x farmakologie $7 D010617
650    _2
$a fosforylace $7 D010766
650    _2
$a aktivace transkripce $x účinky léků $7 D015533
655    _2
$a časopisecké články $7 D016428
700    1_
$a Havelek, Radim $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Kralove 500 38, Czech Republic.
700    1_
$a Cahlíková, Lucie $u ADINACO Research Group, Department of Pharmaceutical Botany and Ecology, Faculty of Pharmacy, Charles University in Prague, Heyrovského 1203, Hradec Králové 500 05, Czech Republic.
700    1_
$a Hulcová, Daniela $u ADINACO Research Group, Department of Pharmaceutical Botany and Ecology, Faculty of Pharmacy, Charles University in Prague, Heyrovského 1203, Hradec Králové 500 05, Czech Republic.
700    1_
$a Mazánková, Naděžda $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Kralove 500 38, Czech Republic.
700    1_
$a Řezáčová, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Kralove 500 38, Czech Republic.
773    0_
$w MED00003830 $t Phytomedicine international journal of phytotherapy and phytopharmacology $x 1618-095X $g Roč. 35, č. - (2017), s. 1-10
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28991639 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180521091839 $b ABA008
999    __
$a ok $b bmc $g 1299917 $s 1013133
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 35 $c - $d 1-10 $e 20170819 $i 1618-095X $m Phytomedicine $n Phytomedicine $x MED00003830
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...